MenuRare cancer patients and researchers need our help.
Insufficient funding for rare cancer research leaves patients with very few, if any, treatment options.
Cost vs. Benefits
Developing treatments for rare cancers is often not financially viable for pharmaceutical companies.1
Due to the lack of funding, researchers lack basic tools needed to make progress. In many cases patients are treated with therapies designed for other cancers.
EXAMPLE
In 2018, the top three cancers funded by the National Cancer Institute received close to $1.2 billion in funding, while esophageal cancer received 2.5% of that amount.2
Clinical trials often offer effective opportunities for treatment in rare cancers, but many barriers prevent patients from enrolling.3
EXAMPLE
The National Cancer Institute estimates there will be 18,440 new cases of esophageal cancer and 16,170 deaths in 2020 alone.4
New Cases
Deaths